Ind-Swift Laboratories quarterly results

Q2 FY27 · Jul–Sep 2026

₹ crore	Q2 FY27	Q2 FY26	Change
Revenue	240	153	+57.5%
EBITDA	45.5	1.5	+2,981.3%
EBITDA margin	18.9%	1.0%	+17.9 pts
Profit before tax	43.4	10.3	+319.4%
Net profit	34.2	8.0	+328.3%
EPS	₹3.94	₹1.00	+294.0%

Every quarter

₹ crore except per share

Tap a line for its trend	Q2 FY27Sep 2026	Q1 FY27Jun 2026	Q4 FY26Mar 2026	Q3 FY26Dec 2025	Q2 FY26Sep 2025	Q1 FY26Jun 2025	Q4 FY25Mar 2025	Q3 FY25Dec 2024	Q2 FY25Sep 2024	Q1 FY25Jun 2024	Q4 FY24Mar 2024	Q3 FY24Dec 2023	Earlier quartersAlpha Plus

Expenses
	240	191	170	151	153	153	138	8.7	12.0	33.2	393	288	Earlier quartersEvery year the company has filed comes with Alpha Plus.
	7.6	7.7	2.2	27.6	17.9	14.6	4.5	13.8	13.0	11.1	25.3	7.1
	248	199	172	178	171	167	143	22.5	25.0	44.3	419	295
	92.9	81.8	74.2	66.0	66.1	65.4	16.3	5.9	7.8	2.1	248	163
	16.1	13.5	7.3	9.8	11.9	8.7	33.9	0.4	0.5	25.2	21.2	1.8
	−2.5	−16.9	−20.0	−5.6	−0.3	−1.0	7.5	0.0	0.0	0.0	44.0	−9.4
	38.0	39.6	37.2	32.0	36.3	32.5	31.3	6.7	5.8	6.1	39.3	37.1
	1.3	0.7	−2.4	0.7	2.0	1.2	−26.8	0.1	0.4	0.2	−11.5	21.1
	7.8	7.6	8.1	8.8	7.0	6.7	7.4	0.2	0.2	0.2	12.7	13.6
	50.5	40.1	50.5	44.5	37.2	43.5	58.4	10.3	9.6	9.5	78.2	43.7
	204	166	155	156	160	157	128	23.6	24.4	43.3	432	271
	45.5	33.4	20.6	4.2	1.5	3.6	−9.2	−14.5	−11.8	−9.7	−37.3	51.3
	37.7	25.9	12.5	−4.7	−5.5	−3.1	−16.6	−14.8	−12.0	−10.0	−50.0	37.7
Profit
	44.0	32.8	17.1	22.2	10.3	10.4	14.6	−1.1	0.6	1.0	−13.3	23.8
	−0.6	−0.2	−5.2	−5.9	0.0	0.0	216	0.0	0.0	0.0	387	0.0
	43.4	32.6	12.0	16.4	10.3	10.4	230	−1.1	0.6	1.0	373	23.8
	9.2	8.0	5.1	4.0	2.3	1.7	4.2	−1.1	0.2	−0.0	145	4.2
	0.0	−0.0	−8.3	0.0	0.0	0.0	4.0	0.0	0.0	0.0	−10.8	0.0
	9.2	8.0	−3.1	4.0	2.3	1.7	8.2	−1.1	0.2	−0.0	134	4.2
	0.0	0.0	0.0	−2.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	0.1	0.1	0.0	0.0	−0.1	0.1	−0.0	0.0	0.0	−0.1	0.0	−0.1
	34.2	24.7	15.1	9.5	8.0	8.8	222	0.0	0.4	0.9	239	19.4
	34.2	24.6	15.1	9.5	8.0	8.6	222	−0.0	0.4	1.0	239	19.5
	2.9	0.1	−0.9	0.0	0.0	0.0	17.2	0.0	0.0	0.0	−0.0	0.0
	37.1	24.8	14.2	9.5	8.0	8.8	239	0.0	0.4	0.9	239	19.4
	—	—	—	—	—	8.8	222	0.0	—	0.9	239	19.4
Per share
	₹3.94	₹2.84	₹1.81	₹1.17	₹1.00	₹1.28	₹32.96	₹0.00	₹0.07	₹0.16	₹40.42	₹3.29
	₹3.92	₹2.84	₹1.76	₹1.13	₹0.96	₹1.17	₹30.08	₹0.00	₹0.07	₹0.16	₹40.42	₹3.29
Other comprehensive income — detail
	2.9	0.1	−0.9	0.0	0.0	0.0	17.2	—	—	—	—	—
	0.0	0.0	0.9	0.0	0.0	0.0	0.0	—	—	—	—	—
	−2.9	−0.1	0.0	0.0	0.0	0.0	−17.2	—	—	—	—	—
	—	—	—	—	—	—	—	—	0.0	0.0	0.0	0.0
	—	24.7	—	—	—	8.8	—	0.0	0.0	0.0	239	19.4
	—	0.0	—	—	—	0.0	—	0.0	0.3	0.0	0.0	0.0
Per share — as-filed variants
	₹3.94	₹2.84	₹1.81	₹1.17	₹1.00	₹1.28	₹32.96	₹0.00	₹0.07	₹0.16	₹40.42	₹3.29
	₹3.92	₹2.84	₹1.76	₹1.13	₹0.96	₹1.17	₹30.08	₹0.00	₹0.07	₹0.16	₹40.42	₹3.29
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	134	113	108	80.6	75.0	79.6	80.5	2.4	3.6	5.9	80.2	132
	55.7%	59.1%	63.8%	53.4%	49.1%	52.1%	58.3%	28.2%	30.5%	17.7%	20.4%	45.9%
Adjusted (ex-exceptional items) — derived
	44.0	32.8	17.1	22.2	10.3	10.4	14.6	−1.1	0.6	1.0	−13.3	23.8
	−0.6	−0.2	−5.2	−5.9	0.0	0.0	216	0.0	0.0	0.0	387	0.0
	34.7	24.9	20.3	14.0	8.0	8.8	14.1	0.0	0.4	0.9	−8.5	19.4
	₹3.99	₹2.86	₹2.43	₹1.71	₹1.00	₹1.28	₹2.09	₹0.00	₹0.07	₹0.16	−₹1.43	₹3.29

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

INDSWFTLAB₹378.95

Ind-Swift Laboratories Limited

· Pharma & Health

Annual Quarterly₹ CrorePeersSMSPHARMA SOLARA DCAL HIKAL UNICHEMLAB GUFICBIO PANACEABIO RPGLIFEMcap ₹3,291 Cr

View

In ₹ Crore except Per Share 3 Months Ending	Q3 FY24 31/12/2023	Q4 FY24 31/03/2024	Q1 FY25 30/06/2024	Q2 FY25 30/09/2024	Q3 FY25 31/12/2024	Q4 FY25 31/03/2025	Q1 FY26 30/06/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026	Q2 FY27 30/09/2026
Revenue from Operations	287.5	393.3	33.2	12.0	8.7	138.2	152.7	152.6	150.9	169.8	191.5	240.5
Other Income	7.1	25.3	11.1	13.0	13.8	4.5	14.6	17.9	27.6	2.2	7.7	7.6
Total Income	294.6	418.6	44.3	25.0	22.5	142.7	167.3	170.5	178.4	172.0	199.1	248.1
Expenses
+ Cost of Materials Consumed	163.1	248.0	2.1	7.8	5.9	16.3	65.4	66.1	66.0	74.2	81.8	92.9
+ Purchases of Stock-in-Trade	1.8	21.2	25.2	0.5	0.4	33.9	8.7	11.9	9.8	7.3	13.5	16.1
+ Changes in Inventories	-9.4	44.0	0.0	0.0	0.0	7.5	-1.0	-0.3	-5.6	-20.0	-16.9	-2.5
+ Employee Benefit Expense	37.1	39.3	6.1	5.8	6.7	31.3	32.5	36.3	32.0	37.2	39.6	38.0
+ Finance Costs	21.1	-11.5	0.2	0.4	0.1	-26.8	1.2	2.0	0.7	-2.4	0.7	1.3
+ Depreciation & Amortisation	13.6	12.7	0.2	0.2	0.2	7.4	6.7	7.0	8.8	8.1	7.6	7.8
+ Other Expenses	43.7	78.2	9.5	9.6	10.3	58.4	43.5	37.2	44.5	50.5	40.1	50.5
Total Expenses	270.9	431.8	43.3	24.4	23.6	128.1	157.0	160.2	156.2	154.9	166.3	204.1
EBITDA	51.3	-37.3	-9.7	-11.8	-14.5	-9.2	3.6	1.5	4.2	20.6	33.4	45.5
EBIT	37.7	-50.0	-10.0	-12.0	-14.8	-16.6	-3.1	-5.5	-4.7	12.5	25.9	37.7
Profit
PBT before Exceptional Items	23.8	-13.3	1.0	0.6	-1.1	14.6	10.4	10.3	22.2	17.1	32.8	44.0
+ Exceptional Items	0.0	386.6	0.0	0.0	0.0	215.9	0.0	0.0	-5.9	-5.2	-0.2	-0.6
Pretax Income	23.8	373.3	1.0	0.6	-1.1	230.5	10.4	10.3	16.4	12.0	32.6	43.4
+ Current Tax	4.2	145.3	-0.0	0.2	-1.1	4.2	1.7	2.3	4.0	5.1	8.0	9.2
+ Deferred Tax	0.0	-10.8	0.0	0.0	0.0	4.0	0.0	0.0	0.0	-8.3	-0.0	0.0
Tax Expense	4.2	134.5	-0.0	0.2	-1.1	8.2	1.7	2.3	4.0	-3.1	8.0	9.2
+ Net Movement in Regulatory Deferral Balances	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.9	0.0	0.0	0.0
+ Share of Associates & JVs	-0.1	0.0	-0.1	0.0	0.0	-0.0	0.1	-0.1	0.0	0.0	0.1	0.1
Net Income	19.4	238.9	0.9	0.4	0.0	222.3	8.8	8.0	9.5	15.1	24.7	34.2
+ Net Income — Continuing Ops	19.5	238.9	1.0	0.4	-0.0	222.3	8.6	8.0	9.5	15.1	24.6	34.2
+ Other Comprehensive Income	0.0	-0.0	0.0	0.0	0.0	17.2	0.0	0.0	0.0	-0.9	0.1	2.9
Total Comprehensive Income	19.4	238.8	0.9	0.4	0.0	239.5	8.8	8.0	9.5	14.2	24.8	37.1
Net Income to Common	19.4	238.9	0.9	—	0.0	222.3	8.8	—	—	—	—	—
Per Share
Basic EPS	3.29	40.42	0.16	0.07	0.00	32.96	1.28	1.00	1.17	1.81	2.84	3.94
Diluted EPS	3.29	40.42	0.16	0.07	0.00	30.08	1.17	0.96	1.13	1.76	2.84	3.92
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	—	—	—	17.2	0.0	0.0	0.0	-0.9	0.1	2.9
+ Tax on Items NOT to be Reclassified	—	—	—	—	—	0.0	0.0	0.0	0.0	0.9	0.0	0.0
+ Tax on Items to be Reclassified	—	—	—	—	—	-17.2	0.0	0.0	0.0	0.0	-0.1	-2.9
+ Tax on Items to be Reclassified — alt tag	0.0	0.0	0.0	0.0	—	—	—	—	—	—	—	—
Comprehensive Income — Owners of Parent	19.4	238.9	0.0	0.0	0.0	—	8.8	—	—	—	24.7	—
Comprehensive Income — Non-controlling Interests	0.0	0.0	0.0	0.3	0.0	—	0.0	—	—	—	0.0	—
Per Share — as-filed variants
Basic EPS — Continuing Operations	3.29	40.42	0.16	0.07	0.00	32.96	1.28	1.00	1.17	1.81	2.84	3.94
Diluted EPS — Continuing Operations	3.29	40.42	0.16	0.07	0.00	30.08	1.17	0.96	1.13	1.76	2.84	3.92
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	132.1	80.2	5.9	3.6	2.4	80.5	79.6	75.0	80.6	108.3	113.1	133.9
Gross Margin %	45.94	20.39	17.65	30.48	28.22	58.26	52.15	49.13	53.44	63.79	59.08	55.70
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	23.8	-13.3	1.0	0.6	-1.1	14.6	10.4	10.3	22.2	17.1	32.8	44.0
− Exceptional Items (reconciliation)	0.0	386.6	0.0	0.0	0.0	215.9	0.0	0.0	-5.9	-5.2	-0.2	-0.6
Net Income Adj (tax-effected)	19.4	-8.5	0.9	0.4	0.0	14.1	8.8	8.0	14.0	20.3	24.9	34.7
EPS Adj	3.29	-1.43	0.16	0.07	0.00	2.09	1.28	1.00	1.71	2.43	2.86	3.99
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00
Filed Debt Equity	1.00	0.00	0.00	—	—	—	0.00	—	—	—	0.00	—
Filed Dscr	2.00	6.00	0.00	—	—	—	0.00	—	—	—	0.00	—
Filed Iscr	3.00	6.00	0.00	—	—	—	0.00	—	—	—	0.00	—
Paid Up Equity Capital	59.1	59.1	59.1	59.1	59.1	68.7	68.7	81.6	81.6	86.8	86.8	87.0

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: Q2 FY27 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Ind-Swift Laboratories Q2 FY27 results (July–September 2026)

Filed with NSE on Thursday, 29 October 2026 at 2:59 pm IST

Ind-Swift Laboratories (NSE: INDSWFTLAB) reported its Q2 FY27 results (July–September 2026) on Thursday, 29 October 2026 at 2:59 pm IST. Consolidated net profit was ₹34.2 crore, up 328.3% from ₹8 crore in Q2 FY26 and up 38.6% from ₹24.7 crore in Q1 FY27. Revenue from operations was ₹240 crore, up 57.5% year on year and up 25.6% from the previous quarter.

Q2 FY26 results (a year earlier): 14 November 2025
Q3 FY27 results due by: 14 February 2027

Q2 FY27 at a glance · consolidated

Net profit: ₹34.2 Cr+328.3% vs Q2 FY26+38.6% vs Q1 FY27
Revenue from operations: ₹240 Cr+57.5% vs Q2 FY26+25.6% vs Q1 FY27
Operating margin (EBIT): 15.7%+19.3 pts vs Q2 FY26+2.2 pts vs Q1 FY27EBIT ₹37.7 Cr
EBITDA: ₹45.5 Cr₹1.5 Cr in Q2 FY26+36.0% vs Q1 FY27margin 18.9%
Earnings per share (basic): ₹3.94+294.0% vs Q2 FY26+38.7% vs Q1 FY27
Net profit margin: 14.2%+9.0 pts vs Q2 FY26+1.3 pts vs Q1 FY27

Questions

What was Ind-Swift Laboratories' net profit in Q2 FY27?

Consolidated net profit was ₹34.2 crore, up 328.3% from ₹8 crore in Q2 FY26 and up 38.6% from ₹24.7 crore in Q1 FY27.

What was Ind-Swift Laboratories' revenue in Q2 FY27?

Revenue from operations was ₹240 crore, up 57.5% year on year and up 25.6% from the previous quarter.

What was Ind-Swift Laboratories' EPS in Q2 FY27?

Basic earnings per share were ₹3.94, against ₹1.00 in Q2 FY26.

How were Ind-Swift Laboratories' Q2 FY27 results?

Both grew from a year earlier: net profit was up 328.3% at ₹34.2 crore and revenue was up 57.5% at ₹240 crore. The operating margin was 15.7%, up 19.3 percentage points from −3.6% a year earlier. Against Q1 FY27, net profit was up 38.6% and revenue up 25.6%.

What was Ind-Swift Laboratories' operating margin in Q2 FY27?

Operating profit (EBIT — revenue less operating expenses, before finance costs and other income) was ₹37.7 crore, a margin of 15.7%, against 13.5% in Q1 FY27 and −3.6% in Q2 FY26. EBITDA was ₹45.5 crore, 18.9% of revenue.

What was Ind-Swift Laboratories' revenue in FY26?

Revenue from operations was ₹641 crore in FY26 (April 2025–March 2026), up 14.2% from ₹562 crore in FY25. It was ₹1,281 crore in FY24 and ₹1,207 crore in FY23: down 46.9% over three years, an average fall of 19.0% a year.

What was Ind-Swift Laboratories' net profit in the first half of FY27?

Consolidated net profit for the first half of FY27 (April–September 2026) was ₹58.9 crore, up 251.4% from ₹16.8 crore in the same months a year earlier. Revenue from operations was ₹432 crore, up 41.4%.

What is Ind-Swift Laboratories' net profit margin?

Ind-Swift Laboratories' net profit margin was 14.2% in Q2 FY27 (net profit as a share of revenue from operations), against 5.2% in Q2 FY26 (up 9.0 percentage points). For FY26 as a whole it was 6.5%.

What was Ind-Swift Laboratories' net profit in FY26?

Consolidated net profit was ₹41.4 crore in FY26 (April 2025–March 2026), down 83.5% from ₹250 crore in FY25. It was ₹421 crore in FY24 and ₹47.6 crore in FY23: down 13.0% over three years, an average fall of 4.5% a year.

How has Ind-Swift Laboratories' profit changed over the last four quarters?

Net profit by quarter: ₹9.5 crore in Q3 FY26, ₹15.1 crore in Q4 FY26, ₹24.7 crore in Q1 FY27 and ₹34.2 crore in Q2 FY27. That is ₹83.6 crore over the four quarters, down 65.0% from ₹239 crore in the four quarters before. Revenue from operations: ₹151 crore, ₹170 crore, ₹191 crore and ₹240 crore.

When did Ind-Swift Laboratories announce its Q2 FY27 results?

On Thursday, 29 October 2026 at 2:59 pm IST, in its results filing to the stock exchanges. A year earlier it reported Q2 FY26 on 14 November 2025.

When will Ind-Swift Laboratories announce its Q3 FY27 results?

Q3 FY27 covers October–December 2026. Listed companies must publish quarterly results within 45 days of the quarter's end (SEBI listing rules, Regulation 33), so the results are due by 14 February 2027. The company tells the exchanges the date of the board meeting at least two working days before it.

Where do these Ind-Swift Laboratories figures come from?

From Ind-Swift Laboratories' own consolidated results filings to NSE, in ₹ crore as filed (Q2 FY27 on 29 October 2026). Growth compares the same consolidated figures a year and a quarter earlier.

Consolidated figures from the company's filings to NSE. Every company's results dates this season are in the Q2 FY27 results calendar, part of Alpha Plus.